Skip to contentB
Boston Scientific Corp
B
BSXBoston Scientific Corp Q2 2026 · 10-Q
Revenue$5.44B$5.44B+7.5% vs Q2 2025 Net Income$905.00M$905.00M+13.8% vs Q2 2025 EPS Diluted$0.61$0.61+15.1% vs Q2 2025 Gross Profit$3,848,000,000+12.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Boston Scientific Corp · CIK 885725 · Engraved from SEC EDGAR
Operating Cash Flowderived$1,474,000,000+14.6% Free Cash Flowderived$1,279,000,000+13.3% Margins · derivedGross margin70.7%+3.1 pt vs Q2 2025
Operating margin21.6%+5.5 pt vs Q2 2025
Net margin16.6%+0.9 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 3, 2026 · 34 d after period end